Itriglumide is a CCK2 receptor antagonist potentially for the treatment of peptic ulcers, dyspepsia, and gastroesophageal reflux disease (GERD). References: Ekstrom J, Cevik Aras H. Parasympathetic non-adrenergic, non-cholinergic transmission in rat parotid glands: effects of cholecystokinin-A and -B receptor antagonists on the secretory response. Regul Pept. 2008 Feb 7;146(1-3):278-84. Epub 2007 Oct 22. PubMed PMID: 18006087.

纯度：≥98%

CAS：201605-51-8